circadian rhythm comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-03-24. Numbers and descriptions here follow the published literature rather than marketing material.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also marketed informally as Stenabolic |
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ |
| Molecular formula | C24H30ClN3O4S | Approximate molecular weight 492 g/mol |
| CAS Registry Number | 1379686-30-2 | Identifier for the parent compound |
| Regulatory status | Not approved for human use | Prohibited in sport by WADA |
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
== External links == Interview with Roderick MacKinnon by Harry Kroto Freeview video provided by the Vega Science Trust. Website of his lab at The Rockefeller University Ion Channel Chemistry: The Electrical System of Life Transcribed video of a May 2008 talk by MacKinnon, sponsored by the Oregon State University Libraries. Nobel Lecture by Roderick MacKinnon, 2003 Introduction to Neuroscience by Donald C.Cooper Roderick MacKinnon on Nobelprize.org
=== Physiology === Potassium is the most abundant intracellular cation. About 98% of the body's potassium is found inside cells, with the remainder in the extracellular fluid, including the blood. Membrane potential is maintained principally by the concentration gradient and membrane permeability to potassium, with some contribution from the Na+/K+ pump. The potassium gradient is critically important for many physiological processes, including maintenance of cellular membrane potential, homeostasis of cell volume, and transmission of action potentials in nerve cells. Potassium is eliminated from the body through the gastrointestinal tract, kidney and sweat glands. In the kidneys, elimination of potassium is passive (through the glomeruli), and reabsorption is active in the proximal tubule and the ascending limb of the loop of Henle. There is active excretion of potassium in the distal tubule and the collecting duct; both are controlled by aldosterone. In sweat glands, potassium elimination is quite similar to the kidney; its excretion is also controlled by aldosterone. Regulation of serum potassium is a function of intake, appropriate distribution between intracellular and extracellular compartments, and effective bodily excretion. In healthy individuals, homeostasis is maintained when cellular uptake and kidney excretion naturally counterbalance a patient's dietary intake of potassium. When kidney function becomes compromised, the ability of the body to effectively regulate serum potassium via the kidney declines.
3-Methylcrotonyl-CoA (β-Methylcrotonyl-CoA or MC-CoA) is an intermediate in the metabolism of leucine. It is found in mitochondria, where it is formed from isovaleryl-coenzyme A by isovaleryl coenzyme A dehydrogenase. It then reacts with CO2 to yield 3-methylglutaconyl-CoA, catalysed by 3-Methylcrotonyl-CoA carboxylase.
=== Pulp stones === Pulp stones are calcified masses that occur in the pulp, either in the apical or coronal portions. They are classified according to their structure or location. According to their location, pulp stones can be classed either as free (completely surrounded by pulp), embedded (surrounded by dentine tissue) or adherent (attached to pulp wall continuous with dentine, but not fully enclosed). Depending on the structure, they are either true (dentine lined by odontoblasts), false (formed from degenerating cells that mineralise) or diffuse (more irregular in shape to false stones). The aetiology of pulp stones is little understood. It has been recorded that pulpal calcifications can occur due to:
Sources: en.wikipedia.org
== Languages == Moluccans speak over a hundred different languages, with a majority of them belonging to the Central Malayo-Polynesian language family. An important exception is the North Moluccan islands which include the island of Halmahera and its surrounding islands, where the majority of the population speak West Papuan languages (North Halmahera branch), possibly brought through historical migration from the Bird's Head Peninsula of New Guinea. Another exception are the Malay-based creoles such as the Ambonese language (also known as Ambonese Malay), spoken mainly on Ambon and the nearby Ceram; and North Moluccan Malay used on the islands of Ternate, Tidore, Halmahera and Sula Islands in North Maluku. Moluccans living in the Netherlands mostly speak Ambonese and Buru, as well as the national and official Dutch language.
Sherman leaves with Richmond and a tennis ball covered in the youth formula and heads to a presentation at Phleer Pharmaceuticals that Buddy is giving about the youth formula. Meanwhile, a worried Denise discovers what has happened and that Sherman's brain damage is progressing. With Cletus' help, Denise goes after him. Sherman takes advantage of the canine DNA crossed with Buddy's and throws the tennis ball to distract him. Buddy catches the ball in his mouth, and the youth formula transforms him back into a toddler, then further into a glowing mass of sentient genetic material. Sherman chases the genetic material, intent on drinking it to correct his condition. However, the material evaporates on the edge of a fountain before he can get to it. Cletus and Denise arrive too late to save him, and Denise breaks into tears, which hit the genetic material and fall into the fountain. As they go to leave, Sherman looks into the fountain, remarking that it is "pretty". Seeing the water is glowing, Denise realizes the genetic material has reconstituted thanks to her tears and that if Sherman drinks the fountain water before it dissipates, he will be restored to normal. Sherman drinks the water and is able to restore his genetic makeup to its proper order, restoring his intelligence. With Buddy Love defeated, Sherman and Denise finally get married. During the wedding reception, Sherman's older brother, Ernie Klump Sr., sings a song in honor of the couple, while Richmond continues to be hexed by the now normal-sized hamster.
GSK-3 functions by phosphorylating a serine or threonine residue on its target substrate. A positively charged pocket adjacent to the active site binds a "priming" phosphate group attached to a serine or threonine four residues C-terminal of the target phosphorylation site. The active site, at residues 181, 200, 97, and 85, binds the terminal phosphate of ATP and transfers it to the target location on the substrate (see figure 1).
The high degree of structural specificity of a broad series of formylated peptides in stimulating these neutrophil responses, the specific binding of N-formylated oligopeptides to neutrophils with affinities that paralleled their stimulating potencies, the ability of t-carbobenzoxy-phenylalanyl-methionine to bind to but not stimulate neutrophils and thereby to block the neutrophil binding and stimulating activity of N-formylated oligopeptides, and the ability of the formylated oligopeptides to desensitize (i.e. render unresponsive) neutrophil functional responses to themselves but have no or a lesser ability to desensitize to a range of other chemotactic stimuli provided strong suggestive evidence that the formylated peptides acted on cells through a common, dedicated receptor system that differed from other chemotactic factor receptors.
== Acquisitions == Bruker acquisitions include GE NMR Instruments (1992), Siemens AXS (1997), Nonius (2001), MacScience (2002), Vacuumschmelze Hanau (2003), Röntec (2005), SOCABIM (2005), PGT (2005), Keymaster (2006), Quantron (2006), JuWe (2008), SIS (2008), ACCEL (2009), Michrom Bioresources (2011), Skyscan (2012), Prairie Technologies (2013), Oncovision (Preclinical PET imaging business, 2016), Oxford Instruments Superconducting Technology (2016), Hysitron Inc. (2017), XGLab (2017), Luxendo (2017), JPK Instruments (2018), Alicona (2018), PMOD Technologies LLC (2019), Canopy Biosciences (2020), Optimal Group (2022), Neurescence Inc (2022), PhenomeX (2023), MIRO Analytical (majority 2023), NanoString Technologies assets (2024), and ELITechGroup (2024).
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that binds and modulates the nuclear receptors REV-ERBα and REV-ERBβ. It is used in laboratory studies of circadian biology and metabolism, not as an approved medicine. It is also known by the informal name Stenabolic.
No. SR9009 has not been approved as a therapeutic drug in the United States, European Union, or other major markets. Human safety and efficacy data are very limited. Its presence in consumer products does not imply regulatory approval.
The World Anti-Doping Agency lists SR9009 as a prohibited substance because it can alter gene expression and metabolic pathways relevant to performance. The ban applies at all times, not only during competition. Detection relies on laboratory methods such as mass spectrometry.
It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.